Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
46
BNTX Quote, Financials, Valuation and Earnings
Last price:
$116.12
Seasonality move
:
11.02%
Day range:
$118.72 - $120.16
52-week range:
$81.20 - $126.77
Dividend yield:
0%
P/E ratio:
191.55x
P/S ratio:
8.12x
P/B ratio:
1.38x
Volume:
904.6K
Avg. volume:
1.2M
1-year change:
-0.34%
Market cap:
$29.9B
Revenue:
$3B
EPS (TTM):
-$2.63
Analysts' Opinion
-
Consensus RatingBioNTech SE has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $140.90, BioNTech SE has an estimated upside of 18.07% from its current price of $119.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $103.12 representing 13.6% downside risk from its current price of $119.34.
Fair Value
-
According to the consensus of 19 analysts, BioNTech SE has 18.07% upside to fair value with a price target of $140.90 per share.
BNTX vs. S&P 500
-
Over the past 5 trading days, BioNTech SE has overperformed the S&P 500 by 12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioNTech SE does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioNTech SE has grown year-over-year revenues for 2 quarters straight. In the most recent quarter BioNTech SE reported revenues of $1.8B.
Earnings Growth
-
BioNTech SE earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioNTech SE reported earnings per share of -$0.14.
Enterprise value:
13.3B
EV / Invested capital:
--
Price / LTM sales:
8.12x
EV / EBIT:
--
EV / Revenue:
3.78x
PEG ratio (5yr expected):
-2.06x
EV / Free cash flow:
-22.65x
Price / Operating cash flow:
25.47x
Enterprise value / EBITDA:
70.79x
Gross Profit (TTM):
$2.9B
Return On Assets:
-2.6%
Net Income Margin (TTM):
-17.92%
Return On Equity:
-3.01%
Return On Invested Capital:
-2.96%
Operating Margin:
41.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $6.9B | $3.3B | $3.5B | $1.4B | $1.8B | |
| Gross Profit | $6.2B | $2.8B | $2.9B | $1.2B | $1.6B | |
| Operating Income | $3.8B | -$266.6M | -$236M | $401.1M | $743.5M | |
| EBITDA | $4B | -$37.8M | $188.5M | $449.9M | $888.6M | |
| Diluted EPS | $11.51 | -$2.15 | -$2.63 | $0.89 | -$0.14 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $15.6B | $20.8B | $19.9B | $20.6B | $18.6B | |
| Total Assets | $16.5B | $22.2B | $23.5B | $25B | $25.1B | |
| Current Liabilities | $5.7B | $3.9B | $1.9B | $2.8B | $2.6B | |
| Total Liabilities | $6.4B | $4.2B | $2.5B | $3.7B | $3.4B | |
| Total Equity | $10.1B | $18B | $21B | $21.3B | $21.7B | |
| Total Debt | $332.3M | $232.2M | $171.4M | $272M | $272.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.5B | $1.6B | -$336.1M | -$687.8M | $854.1M | |
| Cash From Investing | -$4.8B | -$5.7B | $939M | -$162.6M | -$994.8M | |
| Cash From Financing | -$871.2M | -$45M | -$51.6M | -$8.7M | -$14.1M | |
| Free Cash Flow | $4.8B | $1.5B | -$588.9M | -$778.7M | $784.4M | |
BNTX
Sector
Market Cap
$29.9B
$25.9M
Price % of 52-Week High
94.14%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-0.01%
-1.66%
1-Year Price Total Return
-0.34%
-18.99%
Beta (5-Year)
1.393
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$113.80
200-day SMA
Buy
Level
$103.69
Bollinger Bands (100)
Buy
Level
95.76 - 107.66
Chaikin Money Flow
Buy
Level
108.7M
20-day SMA
Buy
Level
$105.14
Relative Strength Index (RSI14)
Buy
Level
72.43
ADX Line
Buy
Level
35.58
Williams %R
Sell
Level
-17.7829
50-day SMA
Buy
Level
$100.56
MACD (12, 26)
Buy
Level
5.52
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
101.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.1636)
Buy
CA Score
(Annual)
Level (1.1576)
Buy
Beneish M-Score
(Annual)
Level (-3.1897)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-4.7692)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Stock Forecast FAQ
In the current month, BNTX has received 15 Buy ratings 4 Hold ratings, and 0 Sell ratings. The BNTX average analyst price target in the past 3 months is $140.90.
-
Where Will BioNTech SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioNTech SE share price will rise to $140.90 per share over the next 12 months.
-
What Do Analysts Say About BioNTech SE?
Analysts are divided on their view about BioNTech SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioNTech SE is a Sell and believe this share price will drop from its current level to $103.12.
-
What Is BioNTech SE's Price Target?
The price target for BioNTech SE over the next 1-year time period is forecast to be $140.90 according to 19 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is BNTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioNTech SE is a Buy. 15 of 19 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BNTX?
You can purchase shares of BioNTech SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioNTech SE shares.
-
What Is The BioNTech SE Share Price Today?
BioNTech SE was last trading at $116.12 per share. This represents the most recent stock quote for BioNTech SE. Yesterday, BioNTech SE closed at $119.34 per share.
-
How To Buy BioNTech SE Stock Online?
In order to purchase BioNTech SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BNTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BNTX
Sector
P/E ratio
191.55x
23.82x
PEG ratio
-2.06x
-0.01x
P/B ratio
1.38x
1.83x
Price / LTM sales
8.12x
1.56x
Growth Metrics
BNTX
Sector
Revenue growth
29.8%
4.18%
Earnings growth
-115.68%
9.66%
Revenue (5-year growth)
89.57%
6.28%
Earnings forecast
-$0.06
-$0.18
Profitability
BNTX
Sector
Profitability FY 2024
$2.4B
$3.1M
Return on invested capital
-2.96%
-32.89%
Return on assets
-2.6%
-29.56%
Return on equity
-3.01%
-38.66%
Earnings Date
Last Earnings Date
Nov
3
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
2
Balance Sheet
BNTX
Sector
Total cash
$16.9B
$25.2M
Short term investments
$7.3B
$25.1M
Total assets
$23.3B
$73M
Long term debt
$272.8M
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 28
Brand Engagement Network, Inc. [BNAI] is up 20.87% over the past day.
Sell
44
SANM alert for Jan 28
Sanmina Corp. [SANM] is up 6.61% over the past day.
Buy
74
CVNA alert for Jan 28
Carvana Co. [CVNA] is down 14.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
